David Esteban Diaz-Perez
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
David Esteban Diaz-Perez has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Ana García-Tello
Servicio de Urología, Hospital Universitario de Getafe, Departamento Clínico, Facultad de Ciencias Biomédicas, Universidad Europea de Madrid, Madrid, España
1 shared publication - Carlos Téllez
Department of Urology, Hospital Universitario de Getafe, Carretera Madrid-Toledo Km 12,500, 28905 Getafe, Madrid, Spain
1 shared publication - Francisco Javier Diaz-Goizueta
Department of Urology, Hospital Universitario de Getafe, Carretera Madrid-Toledo Km 12,500, 28905 Getafe, Madrid, Spain
1 shared publication - Juliusz Jan Szczesniewski
Department of Urology, University Hospital of Getafe, 28905 Getafe, Spain
1 shared publication - Luis Llanes Gonzalez
Urology Department, University Hospital of Getafe, 28905 Getafe, Spain
1 shared publication
Latest Publications
- Open Access
Omitting the Second Bladder Resection: A 3-Year Prospective Pilot Study
Background/Objectives: The study aimed to find out if the patients without a reTURBT, due to changed protocol in our centre because of the COVID-19 pandemic, had presented higher rates of relapse or progression compared to patients treated by standard reTURBT protocol. Methods: A prospective study was conducted including 43 patients with high-risk T1 non-muscle invasive bladder cancer diagnosed between March 2020 and June 2021. Patients were divided into two groups: those who underwent reTURBT and those who did not, due to limitations during the COVID-19 pandemic. All patients received intravesical BCG induction therapy and were followed for 3 years. The institutional research ethics committee approved the study. Results: A total of 43 patients were included, 17 (39.5%) underwent reTURBT and 26 (60.5%) did not. No significant differences were observed in tumour characteristics between groups. Recurrence occurred in 43.8% of the reTURBT group and 15.4% of the non-reTURBT group. Tumour progression to T2G3 was observed only in the reTURBT group. Survival analysis showed no significant differences in recurrence-free survival between groups (p = 0.299). Conclusions: Omitting reTURBT in carefully selected patients did not result in significantly worse oncological outcomes; however, due to the small sample size, the study is underpowered and these findings should be interpreted with caution. Early BCG administration in the non-reTURBT group may have contributed to favourable recurrence-free survival. However, further prospective studies are needed to confirm these findings and define optimal criteria for safely omitting reTURBT.
Open AccessOmitting the Second Bladder Resection: A 3-Year Prospective Pilot Study
Background/Objectives: The study aimed to find out if the patients without a reTURBT, due to changed protocol in our centre because of the COVID-19 pandemic, had presented higher rates of relapse or progression compared to patients treated by standard reTURBT protocol. Methods: A prospective study was conducted including 43 patients with high-risk T1 non-muscle invasive bladder cancer diagnosed between March 2020 and June 2021. Patients were divided into two groups: those who underwent reTURBT and those who did not, due to limitations during the COVID-19 pandemic. All patients received intravesical BCG induction therapy and were followed for 3 years. The institutional research ethics committee approved the study. Results: A total of 43 patients were included, 17 (39.5%) underwent reTURBT and 26 (60.5%) did not. No significant differences were observed in tumour characteristics between groups. Recurrence occurred in 43.8% of the reTURBT group and 15.4% of the non-reTURBT group. Tumour progression to T2G3 was observed only in the reTURBT group. Survival analysis showed no significant differences in recurrence-free survival between groups (p = 0.299). Conclusions: Omitting reTURBT in carefully selected patients did not result in significantly worse oncological outcomes; however, due to the small sample size, the study is underpowered and these findings should be interpreted with caution. Early BCG administration in the non-reTURBT group may have contributed to favourable recurrence-free survival. However, further prospective studies are needed to confirm these findings and define optimal criteria for safely omitting reTURBT.